APO
Apollo Global Management, Inc.
APO's outlook is improving, though it still trails on the overall score.
BAC
Bank of America Corporation
BAC has the edge over APO overall, supported by stronger fundamentals and stronger modeled upside.
APO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| N/A | |
| N/A |
APO's revenue is currently stable, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like APO.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
APO PE Valuation
APO has no meaningful PE right now: it lost money over the past year.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
APO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for APO, with profitability holding steady.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over APO on the outlook, with more favorable profitability expectations.
APO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.14 | — |
| Q3 2026 | -$1.81 | -126% |
| Q2 2026 | $2.75 | -49% |
| Q1 2026 | $1.59 | -72% |
| Q4 2025 | $5.54 | -24% |
| Q3 2025 | $6.86 | -27% |
| Q2 2025 | $5.37 | -42% |
| Q1 2025 | $5.73 | -36% |
| Q4 2024 | $7.33 | -11% |
APO has swung to a loss: it lost $1.81 per share over the past year, after a profit the year before.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over APO on earnings quality, reporting a profit while its opponent remains loss making.
APO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | -52% |
| Q2 2026 | $11.2B | +64% |
| Q1 2026 | $5.1B | -8.8% |
| Q4 2025 | $9.9B | +87% |
| Q3 2025 | $9.8B | +26% |
| Q2 2025 | $6.8B | +13% |
| Q1 2025 | $5.5B | -21% |
| Q4 2024 | $5.3B | -52% |
APO's revenue is growing: $4.7B last quarter, down 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -31% | -60 points |
| Q2 2026 | 22% | +9.9 points |
| Q1 2026 | 5.6% | -16 points |
| Q4 2025 | 18% | -15 points |
| Q3 2025 | 30% | +2.7 points |
| Q2 2025 | 12% | -12 points |
| Q1 2025 | 21% | -9.8 points |
| Q4 2024 | 33% | +15 points |
APO's operating margin was −31% last quarter, down 60 points from the same quarter a year ago.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over APO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over APO on profitability, with a higher operating margin.
APO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $136M | -55% |
| Q2 2026 | $2.9B | +128% |
| Q1 2026 | $1.6B | +60% |
| Q4 2025 | $4.7B | +$4.7B |
| Q3 2025 | $303M | -84% |
| Q2 2025 | $1.3B | -5.3% |
| Q1 2025 | $1B | +1346% |
| Q4 2024 | -$4M | -100% |
APO's free cash flow was $9.3B over the past year, about four times what it generated the year before. Free cash flow isn't a meaningful measure for financial services companies like APO.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
APO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -7.6M shares |
| 1 year | -0.9% | -5.2M shares |
| 3 years | +4.1% | +23.8M shares |
| 5 years | +152% | +363M shares |
| Available history | +170% | +380M shares |
APO has 603M diluted shares, down 0.9% from a year ago, with $1.1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $118M |
| Q2 2026 | $97M |
| Q1 2026 | $632M |
| Q4 2025 | $240M |
| Q3 2025 | $340M |
| Q2 2025 | — |
| Q1 2025 | $193M |
| Q4 2024 | $102M |
APO spent $1.1B buying back its own shares over the past year, up 71% from the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over APO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
APO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -1.1x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
APO has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
APO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.7 | Neutral |
| Stochastic | 23.4 | Neutral |
APO's weekly RSI is 49 (neutral) and its Stochastic is 23 (neutral).
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
APO PE vs Financial Services Sector
| Metric | APO | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 13x | 224% above |
| PE % | 85 | 63 | 22 pts above |
APO has no meaningful PE right now: it lost money over the past year.
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over APO on valuation relative to its sector.
APO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.5 | 4.2% above |
| 20 week MA | $123.2 | 1.5% below |
| 50 week MA | $126.1 | 3.7% below |
| 100 week MA | $133.4 | 9% below |
| 200 week MA | $116.4 | 4.2% above |
APO has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
APO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.1 | $49.1 | +2.1% |
| 2021 | $49.1 | $74.3 | +51% |
| 2022 | $74.3 | $64.3 | -13% |
| 2023 | $64.3 | $93.2 | +45% |
| 2024 | $93.2 | $170.3 | +83% |
| 2025 | $170.3 | $148.5 | -13% |
| 2026 YTD | $148.5 | $121.4 | -18% |
APO has finished higher in four of the last six years, two of them by more than 50%. It's down 18% so far in 2026.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over APO on returns for 2026, with the stronger performance.